Interaksi Venlafaksin

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (label Amfetamin, Peringatan dan perhatian)

Discontinue treatment with ADDERALL XR and any concomitant serotonergic agents immediately if symptoms of serotonin syndrome occur, and initiate supportive symptomatic treatment. (label Amfetamin dan dekstroamfetamin, Peringatan dan perhatian)

Reserve the combination of amiodarone with other antiarrhythmic therapies that prolong the QTc to patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent. (label Amiodaron, Peringatan dan perhatian)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (label Azitromisin, Peringatan dan perhatian)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (label Beladona dan opium, Interaksi obat)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Buprenorfin, Interaksi obat)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (label Buprenorfin dan nalokson, Interaksi obat)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Butalbital, aspirin, kafein, dan kodein, Interaksi obat)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (label Butalbital, parasetamol, kafein, dan kodein, Interaksi obat)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (label Butorfanol, Perhatian)

Serotonergic Drugs The concomitant use of dextroamphetamine sulfate and serotonergic drugs increases the risk of serotonin syndrome. (label Dekstroamfetamin, Interaksi obat)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents The use of dofetilide in conjunction with other drugs that prolong the QT interval has not been studied and is not recommended. (label Dofetilid, Peringatan)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

…(12.3) ] • Concomitant use of drugs or herbal products that prolong the QT interval and might increase the risk of torsade de pointes, such as phenothiazine antipsychotics, tricyclic antidepressants, certain oral macrolide antibiotics, and Class I and III antiarrhythmics • Liver or lung toxicity related to the previous use of amiodarone • QTc interval >500 ms or… (label Dronedaron, Kontraindikasi)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

Anticoagulants, Antiplatelets, Thrombolytics, and Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs): Avoid concomitant use due to increased risk of bleeding. (label Edoksaban, Interaksi obat)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

Concomitant use of COMPLERA with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (label Emtrisitabin, rilpivirin, dan tenofovir, Peringatan dan perhatian)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

Drugs that Prolong the QT Interval : Avoid concomitant use. (label Fenobarbital, Interaksi obat)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (label Fentanil, Peringatan dan perhatian)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (label Flukonazol, Kontraindikasi)

THESE ARE MOST FREQUENT IN PATIENTS WHO HAVE BEEN ON BENZODIAZEPINES FOR LONG-TERM SEDATION OR IN OVERDOSE CASES WHERE PATIENTS ARE SHOWING SIGNS OF SERIOUS CYCLIC ANTIDEPRESSANT OVERDOSE. (label Flumazenil, Peringatan kotak hitam)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. (label Fosfomisin, Interaksi obat)

(See DOSAGE and ADMINISTRATION. ) Because of the risk of QT prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic… (label Foskarnet, Interaksi obat)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Hidrokodon, Interaksi obat)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Hidrokodon dan homatropin, Interaksi obat)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (label Hidrokodon dan ibuprofen, Perhatian)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (label Hidrokodon dan klorfeniramin, Interaksi obat)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (label Hidrokodon dan parasetamol, Perhatian)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (label Hidroksiklorokuin, Peringatan dan perhatian)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Hidromorfon, Interaksi obat)

Avoid the use of FANAPT in combination with any other drugs that prolong the QT interval [see Warnings and Precautions (5.3) ] . (label Iloperidon, Interaksi obat)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

Serotonin Syndrome and MAOIs: Do not use MAOI’s intended to treat psychiatric disorders with Venlafaxine Extended Release Tablets or within 7 days of stopping treatment with Venlafaxine Extended Release Tablets. (label Venlafaksin, Kontraindikasi)

Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (label Ivabradin, Peringatan dan perhatian)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (label Karbamazepin, Kontraindikasi)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (label Kodein, Interaksi obat)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval ( 5.11 , 8.5 ) (label Levofloksasin, Peringatan dan perhatian)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (label Levorfanol, Perhatian)

In addition, do not start Venlafaxine Extended Release Tablets in a patient who is being treated with linezolid or intravenous methylene blue ( 4.1 ). (label Venlafaksin, Kontraindikasi)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (label Lisdeksamfetamin, Peringatan dan perhatian)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

Avoid use in patients with congenital long QT syndrome, those with hypokalemia, and with other drugs that prolong the QT interval. (label Lopinavir dan ritonavir, Peringatan dan perhatian)

LOREEV XR should not be used in such patients without adequate antidepressant therapy. (label Lorazepam, Peringatan dan perhatian)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (label Metadon, Peringatan dan perhatian)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (label Metaksalon, Interaksi obat)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (label Metamfetamin, Peringatan dan perhatian)

In addition, do not start Venlafaxine Extended Release Tablets in a patient who is being treated with linezolid or intravenous methylene blue ( 4.1 ). (label Venlafaksin, Kontraindikasi)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (label Morfin, Interaksi obat)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval. (label Oksaliplatin, Interaksi obat)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (label Oksikodon, Interaksi obat)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Oksimorfon, Interaksi obat)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Oliseridin, Interaksi obat)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (label Parasetamol dan kodein, Perhatian)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (label Pentazosin dan nalokson, Perhatian)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

Because pimozide prolongs the QT interval of the electrocardiogram it is contraindicated in patients with congenital long QT syndrome, patients with a history of cardiac arrhythmias, patients taking other drugs which prolong the QT interval of the electrocardiogram or patients with known hypokalemia or hypomagnesemia (see also PRECAUTIONS - DRUG INTERACTIONS ). (label Pimozid, Kontraindikasi)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (label Pitolisant, Peringatan dan perhatian)

…prolong, or intensify the sedative action of other central-nervous-system depressants, such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore, such agents should be avoided or administered in reduced dosage to patients receiving promethazine HCl. (label Prometazin, Interaksi obat)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (label Prometazin dan kodein, Interaksi obat)

• Avoid use with other antiarrhythmic agents or drugs that prolong the QT interval. (label Propafenon, Peringatan dan perhatian)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

Serotonin Syndrome and MAOIs: Do not use MAOI’s intended to treat psychiatric disorders with Venlafaxine Extended Release Tablets or within 7 days of stopping treatment with Venlafaxine Extended Release Tablets. (label Venlafaksin, Kontraindikasi)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (label Remifentanil, Peringatan dan perhatian)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

Serotonin Syndrome and MAOIs: Do not use MAOI’s intended to treat psychiatric disorders with Venlafaxine Extended Release Tablets or within 7 days of stopping treatment with Venlafaxine Extended Release Tablets. (label Venlafaksin, Kontraindikasi)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval. (label Siprofloksasin, Peringatan dan perhatian)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

Mengombinasikan St. John's wort dengan antidepresan dan obat serotonergik lain meningkatkan risiko sindrom serotonin. (NCCIH, St. John's Wort)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

Certain conditions may increase the risk for torsade de pointes or sudden death such as (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval [see Warnings and Precautions ( 5.8 ), Clinical Pharmacology (12.2) ]. (label Tetrabenazin, Interaksi obat)

CONTRAINDICATIONS Thioridazine hydrochloride tablet use should be avoided in combination with other drugs that are known to prolong the QTc interval and in patients with congenital long QT syndrome or a history of cardiac arrhythmias. (label Tioridazin, Kontraindikasi)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (label Vepdegestrant, Peringatan dan perhatian)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (label Venlafaksin, Peringatan kotak hitam)

…drugs, ziprasidone is contraindicated: • in patients with a known history of QT prolongation (including congenital long QT syndrome) • in patients with recent acute myocardial infarction • in patients with uncompensated heart failure Pharmacokinetic/pharmacodynamic studies between ziprasidone and other drugs that prolong the QT interval have not been performed. (label Ziprasidon, Kontraindikasi)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (label Venlafaksin, Peringatan dan perhatian)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (label Venlafaksin, Interaksi obat)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (label Arformoterol, Interaksi obat)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (label Venlafaksin, Peringatan dan perhatian)

The administration of local anesthetic solutions containing epinephrine to patients receiving monoamine oxidase inhibitors, nonselective beta-adrenergic antagonists, or tricyclic antidepressants may produce severe, prolonged hypertension. (label Artikain dan epinefrin, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. (label Venlafaksin, Peringatan dan perhatian)

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. (label Venlafaksin, Peringatan dan perhatian)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (label Venlafaksin, Peringatan dan perhatian)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (label Bismut subsitrat, metronidazol, dan tetrasiklin, Peringatan dan perhatian)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Caution is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines. (label Brimonidin, Interaksi obat)

Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines. (label Brimonidin dan timolol, Interaksi obat)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (label Budesonid dan formoterol, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

…Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants may… (label Bupivakain, Peringatan dan perhatian)

…Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants may… (label Bupivakain dan epinefrin, Peringatan dan perhatian)

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. (label Venlafaksin, Peringatan dan perhatian)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (label Venlafaksin, Peringatan dan perhatian)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (label Daridoreksant, Peringatan dan perhatian)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (label Venlafaksin, Interaksi obat)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (label Venlafaksin, Interaksi obat)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (label Venlafaksin, Interaksi obat)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (label Venlafaksin, Peringatan dan perhatian)

Carefully monitor cardiac rhythm when administering SUPRANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (label Desfluran, Peringatan dan perhatian)

…that may Increase Risk of Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin… (label Desmopresin, Interaksi obat)

Diazepam Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects. (label Venlafaksin, Interaksi obat)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (label Venlafaksin, Peringatan dan perhatian)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (label Venlafaksin, Interaksi obat)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

…drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (label Disikloverin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (label Dronabinol, Peringatan dan perhatian)

…cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see PRECAUTIONS, Drug Interactions ), and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs… (label Droperidol, Peringatan)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (label Venlafaksin, Interaksi obat)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (label Venlafaksin, Interaksi obat)

Monoamine Oxidase Inhibitors (MAOIs) [See Dosage and Administration ( 2.6 and 2.7 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.2 ) . ] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (label Venlafaksin, Interaksi obat)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

• Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (label Epinefrin, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (label Venlafaksin, Peringatan dan perhatian)

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. (label Eribulin, Peringatan dan perhatian)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (label Venlafaksin, Interaksi obat)

Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (label Eszopiklon, Peringatan dan perhatian)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (label Venlafaksin, Peringatan dan perhatian)

Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (label Fenilefrin, Interaksi obat)

…Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine,… (label Fenitoin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (label Venlafaksin, Peringatan dan perhatian)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (label Venlafaksin, Peringatan dan perhatian)

Acute cardiac arrest may be possible during treatment with tricyclic antidepressants; therefore, Anticholium should only be considered as an antidote for this indication while the patient has continuous ECG monitoring. (label Fisostigmin, Peringatan dan perhatian)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (label Flutikason dan salmeterol, Interaksi obat)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

• MAO inhibitors, tricyclic antidepressants and drugs that prolong QTc interval may potentiate effect on the cardiovascular system. (label Formoterol, Interaksi obat)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (label Venlafaksin, Interaksi obat)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (label Venlafaksin, Interaksi obat)

…Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine,… (label Fosfenitoin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

Other Anticholinergic Drugs There is potential for an additive interaction between glycopyrrolate and concomitantly used anticholinergic drugs (e.g., tricyclic antidepressants, anti-epileptics, class I antiarrhythmics, anti­-spasmodics, amantadine) resulting in increased anticholinergic adverse reactions. (label Glikopironium, Interaksi obat)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (label Goserelin, Peringatan dan perhatian)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Haloperidol: Increase in Haloperidol AUC and C max . (label Venlafaksin, Interaksi obat)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (label Venlafaksin, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Monoamine Oxidase Inhibitors or Tricyclic Antidepressants Ipratropium Bromide and Albuterol Sulfate Inhalation Solution should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents because the action of albuterol sulfate on the cardiovascular… (label Ipratropium dan salbutamol, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

Monitor QT interval when administering FORANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (label Isofluran, Peringatan dan perhatian)

Drugs that may potentiate clinical response of Isoproterenol Clinical Impact The effects of isoproterenol may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine. (label Isoprenalin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (label Venlafaksin, Interaksi obat)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (label Karbidopa, levodopa, dan entakapon, Interaksi obat)

Since the sedative effects of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive, appropriate caution should be exercised with patients who take more than one of these CNS depressants simultaneously. (label Karisoprodol, Peringatan dan perhatian)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max . (label Venlafaksin, Interaksi obat)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (label Venlafaksin, Interaksi obat)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (label Venlafaksin, Interaksi obat)

…Interactions The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs. (label Klonazepam, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (label Klopidogrel, Interaksi obat)

The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants. (label Klorazepat, Interaksi obat)

Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (label Kloroprokain, Perhatian)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

Sympathomimetics, postganglionic blocking agents, and tricyclic antidepressants: Concomitant administration may increase the risk of cardiovascular adverse reactions. (label Kokain, Interaksi obat)

It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. (label Kuetiapin, Peringatan dan perhatian)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

TYKERB may prolong the QT interval in some patients. (label Lapatinib, Peringatan dan perhatian)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (label Lemboreksant, Peringatan dan perhatian)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (label Venlafaksin, Interaksi obat)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (label Leuprorelin, Peringatan dan perhatian)

Monoamine oxidase inhibitors (MAOs) or tricyclic antidepressants : May potentiate effect of albuterol on the cardiovascular system. (label Levosalbutamol, Interaksi obat)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (label Levotiroksin, Interaksi obat)

Clinically Significant Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. (label Lidokain, Interaksi obat)

…Adverse Reactions Due to Drug Interactions with FLAVALTA Risk of Severe, Persistent Hypertension Due to Drug Interactions Between FLAVALTA and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of FLAVALTA (containing a vasoconstrictor, epinephrine) in patients receiving monoamine oxidase inhibitors (MAOI), or tricyclic antidepressants may result… (label Lidokain dan epinefrin, Peringatan dan perhatian)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and liothyronine sodium may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (label Liotironin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (label Lumateperon, Peringatan dan perhatian)

Activation of Mania/Hypomania Antidepressant treatment can increase the risk of developing a manic or hypomanic episode, particularly in patients with bipolar disorder. (label Lurasidon, Peringatan dan perhatian)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (label Meflokuin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Likewise, solutions of mepivacaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result. (label Mepivakain, Peringatan)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (label Venlafaksin, Peringatan dan perhatian)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

Caution should be exercised with co-administration of venlafaxine and metoprolol. (label Venlafaksin, Interaksi obat)

Caution should be exercised with co-administration of venlafaxine and metoprolol. (label Venlafaksin, Interaksi obat)

Drugs that Prolong the QT Interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. (label Metronidazol, Interaksi obat)

Drug interactions Additive anticholinergic effects may result from concomitant use with antipsychotics, tricyclic antidepressants, and other drugs with anticholinergic effects. (label Metskopolamin, Interaksi obat)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (label Venlafaksin, Interaksi obat)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (label Venlafaksin, Peringatan dan perhatian)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. (label Moksifloksasin, Peringatan dan perhatian)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Monoamine Oxidase Inhibitors (MAOIs) [See Dosage and Administration ( 2.6 and 2.7 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.2 ) . ] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (label Venlafaksin, Interaksi obat)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

The concurrent use of Xyrem with other CNS depressants, including but not limited to opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, sedating anti-epileptic drugs, general anesthetics, muscle relaxants, and/or illicit CNS depressants, may increase the risk of respiratory depression, hypotension, profound sedation, syncope, and… (label Natrium oksibat, Peringatan dan perhatian)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (label Venlafaksin, Interaksi obat)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Monoamine Oxidase Inhibitors (MAOIs) [See Dosage and Administration ( 2.6 and 2.7 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.2 ) . ] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. (label Venlafaksin, Peringatan dan perhatian)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (label Venlafaksin, Interaksi obat)

…combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval. (label Paliperidon, Peringatan dan perhatian)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (label Pasireotid, Interaksi obat)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Anti-Arrhythmic Drugs, QT Prolonging Drugs, Drugs that may Decrease Heart Rate PONVORY has not been studied in patients taking QT prolonging drugs. (label Ponesimod, Interaksi obat)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

…Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration of local anesthetic injections containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (label Prilokain dan epinefrin, Interaksi obat)

QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between Primaquine phosphate Tablets and other drugs that effect cardiac conduction is unknown. (label Primakuin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (label Venlafaksin, Interaksi obat)

…5-HT 3 Receptor Antagonists Ondansetron Decrease exposure Statins Metabolized by CYP3A4 Simvastatin Decrease exposure Thiazolidinediones Rosiglitazone Decrease AUC by 66% Tricyclic Antidepressants Nortriptyline A tuberculosis treatment regimen including rifampin (600 mg/day), isoniazid (300 mg/day), pyrazinamide (500 mg 3× per day), and pyridoxine (25 mg) was… (label Rifampisin, Interaksi obat)

…levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline, nortriptyline 7.5 Other Interactions The conversion of PRIFTIN to 25-desacetyl rifapentine is mediated by an esterase enzyme. (label Rifapentin, Interaksi obat)

In healthy subjects, 75 mg once daily and 300 mg once daily (3 times and 12 times the dose in EDURANT) have been shown to prolong the QTc interval of the electrocardiogram. (label Rilpivirin, Peringatan dan perhatian)

Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC. (label Venlafaksin, Interaksi obat)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (label Venlafaksin, Interaksi obat)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies ( 14.3 )]. (label Rokuronium, Peringatan dan perhatian)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (label Salbutamol, Interaksi obat)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (label Salmeterol, Interaksi obat)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (label Venlafaksin, Interaksi obat)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (label Sevofluran, Peringatan)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (label Venlafaksin, Interaksi obat)

Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. (label Venlafaksin, Interaksi obat)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (label Venlafaksin, Interaksi obat)

Concomitant use of other drugs that cause central nervous system (CNS) adverse reactions (e.g., alcohol, sedatives, hypnotics, opiates, and anxiolytics) or have anticholinergic properties (e.g., other belladonna alkaloids, sedating antihistamines, meclizine, tricyclic antidepressants, and muscle relaxants) may increase this effect [see Drug Interactions ( 7.1 )] . (label Skopolamin, Peringatan dan perhatian)

Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (label Sorafenib, Peringatan dan perhatian)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (label Sotalol, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

The efficacy of tricyclic antidepressants can decrease when coadministered with sulfamethoxazole and trimethoprim. (label Sulfametoksazol dan trimetoprim (kotrimoksazol), Interaksi obat)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (label Sunitinib, Interaksi obat)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

The benzodiazepines, including temazepam, produce additive CNS-depressant effects when co-administered with other CNS depressants such as alcohol, barbiturates, antipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. (label Temazepam, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (label Venlafaksin, Interaksi obat)

Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (label Terbutalin, Perhatian)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (label Venlafaksin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (label Venlafaksin, Peringatan dan perhatian)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

…quinidine, procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin, levofloxacin, ofloxacin); and certain anti-emetics (e.g., ondansetron, granisetron). (label Toremifen, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (label Triptorelin, Peringatan dan perhatian)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (label Umeklidinium dan vilanterol, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

Drugs Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasostrict ® . (label Vasopresin, Interaksi obat)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (label Venlafaksin, Interaksi obat)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (label Venlafaksin, Interaksi obat)

Patients receiving warfarin therapy should be carefully monitored when Venlafaxine Extended-Release Tablets are initiated or discontinued [see Warnings and Precautions ( 5.13 )] . (label Venlafaksin, Interaksi obat)

Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine. (label Zaleplon, Interaksi obat)

Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use [see Drug Interactions (7.1) ] . (label Zolpidem, Peringatan dan perhatian)

Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine. (label Venlafaksin, Interaksi obat)

This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine. (label Venlafaksin, Interaksi obat)

In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (label Asam valproat, Interaksi obat)

During marketing of venlafaxine hydrochloride extended-release capsules, other SNRI’s (Serotonin and Norepinephrine Reuptake Inhibitors), and SSRI’s (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse reactions occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood,… (label Venlafaksin, Peringatan dan perhatian)

Paralytic ileus, hyperthermia and heat stroke, all of which have sometimes been fatal, have occurred in patients taking anticholinergic-type antiparkinsonism drugs, including benztropine mesylate, in combination with phenothiazines and/or tricyclic antidepressants. (label Benztropin, Peringatan)

However, there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression. (label Brekspiprazol, Peringatan dan perhatian)

CYP1A2 Venlafaxine did not inhibit CYP1A2 in vitro . (label Venlafaksin, Interaksi obat)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (label Venlafaksin, Interaksi obat)

In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (label Divalproeks (valproat), Interaksi obat)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (label Venlafaksin, Interaksi obat)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (label Venlafaksin, Interaksi obat)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (label Venlafaksin, Interaksi obat)

…quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, certain antipsychotics (e.g., ziprasidone, iloperidone, clozapine, quetiapine, chlorpromazine), certain antidepressants (e.g., citalopram, fluoxetine), certain antibiotics (e.g., azithromycin, erythromycin, clarithromycin, gatifloxacin, moxifloxacin); and others (e.g., pentamidine, methadone,… (label Hidroksizin, Perhatian)

This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate. (label Venlafaksin, Interaksi obat)

CYP1A2 Venlafaxine did not inhibit CYP1A2 in vitro . (label Venlafaksin, Interaksi obat)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (label Venlafaksin, Interaksi obat)

There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and carbidopa-levodopa preparations. (label Karbidopa, Interaksi obat)

…placebo-controlled trials of adult patients with major depressive disorder, the proportion of patients with shifts in fasting glucose from normal (<100 mg/dL) to high (≥126 mg/dL) was greatest in the VRAYLAR 3 mg per day + antidepressant therapy arm (3.2%) compared with those taking VRAYLAR 1.5 mg per day + antidepressant therapy (2%) or those placebo-treated (1.3%). (label Kariprazin, Peringatan dan perhatian)

Postmarketing Spontaneous Drug Interaction Reports There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine. (label Venlafaksin, Interaksi obat)

These include itraconazole, ketoconazole, posaconazole, voriconazole, the macrolide antibiotics erythromycin and clarithromycin, the ketolide antibiotic telithromycin, HIV protease inhibitors, boceprevir, telaprevir, the antidepressant nefazodone, or cobicistat-containing products. (label Lovastatin, Peringatan)

CYP1A2 Venlafaxine did not inhibit CYP1A2 in vitro . (label Venlafaksin, Interaksi obat)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (label Venlafaksin, Interaksi obat)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (label Venlafaksin, Interaksi obat)

Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, β-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). (label Perfenazin, Interaksi obat)

In most cases, patients were using concomitant medications (antidepressants, antipsychotics, stimulants, narcotics) that are thought to lower the seizure threshold. (label Tiagabin, Peringatan)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (label Triheksifenidil, Interaksi obat)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (label Venlafaksin, Interaksi obat)

During marketing of venlafaxine hydrochloride extended-release capsules, other SNRI’s (Serotonin and Norepinephrine Reuptake Inhibitors), and SSRI’s (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse reactions occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood,… (label Venlafaksin, Peringatan dan perhatian)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (label Venlafaksin, Interaksi obat)

CYP1A2 Venlafaxine did not inhibit CYP1A2 in vitro . (label Venlafaksin, Interaksi obat)

In addition, no dosage adjustment is necessary for substrates of CYP2D6 (e.g., dextromethorphan, fluoxetine, paroxetine, or venlafaxine), CYP2C9 (e.g., warfarin), CYP2C19 (e.g., omeprazole, warfarin), or CYP3A4 (e.g., dextromethorphan) when coadministered with ABILIFY MAINTENA. (label Aripiprazol, Interaksi obat)

No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa and dopa-decarboxylase inhibitor. (label Entakapon, Perhatian)

Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (label Ropinirol, Interaksi obat)